CFO Studio | Monthly Archives: April 2016 | Page 2April 2016 - Page 2 of 13

Rightsizing the Portfolio

As Seen in CFO Studio Magazine Q4 2015 Issue

By Robert Kossar Executive Managing Director

Real estate plays a role in productivity and innovation

As demands on the C-suite continue to shift, executive leaders are demanding change in the structure and cost profile of their real estate portfolios. Although typical concerns regarding real estate still include whether or not there is too much space, too little space, or the wrong kind of space for the company’s operations and culture, decisions must also be made about the ways employees use the workplace, based on activity.

Today’s CFO helps determine how real estate supports the broader needs of the business, beyond square footage. Working with internal stakeholders, the CFO helps set real-estate objectives and helps determine the financial and operational impact of the company’s portfolio. Organizational success relies on this integration of internal groups across the organization, connecting them to the C-suite, to better empower all levels of workers and drive change.

As CFOs better understand workplace strategy trends, they can also best determine portfolio needs to attract and retain talent who can focus on innovation and increase productivity. Leveraging space-utilization studies and the latest technology to determine space requirements and configurations can help CFOs make real estate an integral part of the business equation. In cases where commercial real estate (CRE) experts are engaged in the organization’s real-estate process, they understand the bottom-line focus of CFOs, and to that end, incorporate tactics to increase portfolio flexibility, improve the environmental efficiencies of each building in the portfolio, and adjust occupational density for the company’s workforce to help reduce cost and deliver savings.

CFOs can rely on CRE experts to provide processes, vendor access, owner/occupier relationships, market intelligence, opportunities for incentives, valuations, sustainability measures, and data technology to provide the company with a competitive edge. The C-suite continues to drive out waste to achieve a competitive advantage in the market. It remains imperative that CFOs constantly evaluate and re-evaluate their business’ real-estate needs, and ensure optimal efficiency and productivity while striving to manage costs.

2016 CFO Innovation Conference: Bio-tech and Pharma Panel

George Parise, CFO of Princeton BioPharma LLC, Barry Lederman, CFO of Halo Pharma, Andrew Einhorn, CFO of Edge Therapeutics, Jim Mastakas, SVP & CFO of Amneal Pharmaceuticals, and Brian Zietsman, President & CFO of Enteris BioPharma will be presenting Bio-tech and Pharma discussion, moderated by Mark Giamo, New Jersey Office Managing Partner, BDO, at 3:15 P.M., May 5th, MetLife Stadium, East Rutherford, NJ.CFOs and senior finance executives may attend at no cost, and non-CFOs may purchase tickets, by registering at www.CFOstudio.com.

Mark Giamo, New Jersey Office Managing Partner, BDO

In his role as New Jersey Office Managing Partner for BDO USA, LLP, Mark is responsible for managing all aspects of the assurance practice for BDO’s New Jersey Office. Mark also co-leads the NY Metro Technology Practice. Mark joined BDO in 1997 and has serviced publicly-traded, private, multi-national, private equity sponsored and growth-oriented companies in the technology industry. Mark spends a significant amount of time servicing SEC registrants as both the engagement partner and technical partner reviewer. In addition, Mark acts as an instructor for continuing education and plays an active role in the firm’s internal quality inspection program.

Some of Mark’s professional affiliations include American Institute of Certified Public Accountants (AICPA), New Jersey State Society of Certified Public Accountants, Board of Directors, Special Olympics of New Jersey, and the Board of Directors, New Jersey Technology Council.

Mark received a B.S. in Accounting from Villanova University.

Barry Lederman, Chief Financial Officer, Halo Pharma

Barry Lederman has extensive financial and international pharmaceutical experience, having led teams of several public and private companies with global operations. Prior to joining Halo, he served as the Vice President and CFO for Eisai Inc. with operations in the Americas Region, the CFO at Wedgewood Pharmacy, Nycomed US Inc., and Qualitrol Company LLC (a subsidiary of Danaher Corporation). He also spent 10 years with Roche in positions of increasing responsibility within Finance, culminating in his appointment as Senior Vice President – Head of Business Analysis and Controlling at Roche Centralized Diagnostics, headquartered in Mannheim, Germany. He is a CPA licensed in New Jersey and New York and gained his accounting experience at PwC.

Andrew Einhorn, Chief Financial Officer, Edge Therapeutics

Andrew Einhorn is the Chief Financial Officer of Edge Therapeutics, Inc. Previously, he served as the Executive Vice President, Corporate Development of the company. Mr. Einhorn has more than 10 years of experience in the pharmaceutical industry developing and executing corporate strategy. He also has more than 20 years of experience as an investment banker working extensively in corporate finance, capital markets and financial analysis. His experience includes numerous acquisition and licensing transactions across a variety of therapeutic areas and geographies.

Prior to joining Edge Therapeutics, Mr. Einhorn was an independent consultant, served as CFO at Myos Corporation and was the Executive Vice President and Chief Financial Officer at Oceana Therapeutics, Inc.

Mr. Einhorn was licensed as a Certified Public Accountant in New Jersey and a graduate of The American University where he completed a double major in Finance and Accounting.

Jim Mastakas, Senior Vice President and Chief Financial Officer, Amneal Pharmaceuticals

Jim oversees the global financial operations of the organization, including strategic planning, budgeting and forecasting, investment decisions, external financing, debt compliance, financial analysis and tax planning. In addition, he is responsible for the IT function. Jim has more than 18 years of experience in the pharmaceutical industry, including thirteen years in generics and specialty sectors. Prior to joining Amneal, Jim was chief financial officer at Sandoz NA, Eagle Pharmaceuticals and Corepharma, and vice president/controller for Mylan’s generic business. He also spent five years at Wyeth leading their External Reporting team. Jim holds a bachelor’s degree in accountancy from Bentley University and is a certified public accountant.

Brian Zietsman, President & Chief Financial Officer, Enteris BioPharma

Mr. Brian Zietsman, President and Chief Financial Officer, joined the Company in July 2013. He brings more than 20 years of strategic finance and accounting experience to his position, over half of which has been in the pharmaceutical industry for both public and private companies.

Prior to joining Enteris BioPharma, Mr. Zietsman was the Chief Financial Officer of Unigene Laboratories, Inc. where he played a pivotal role in that company’s restructuring. Prior to working at Unigene, he was the Corporate Controller at Duff & Phelps (NYSE DUF) and between 2005 and 2011, he worked in various financial capacities at Enzon Pharmaceuticals, Inc., (NASDAQ – ENZN), including Vice President and Corporate Controller. Prior to Enzon, Mr. Zietsman was the Corporate Controller at Reliant Pharmaceuticals, Inc., a privately held company which was acquired by GlaxoSmithKline, and earlier worked at Deloitte where he held various positions of increasing responsibility, leaving as a Senior Manager in the audit group.

Mr. Zietsman is a graduate from Rhodes University, South Africa where he earned his B. Com (Accounting), BSc (Computer Science) and HDIPACC certifications. Mr. Zietsman is a registered CPA.

Should I Take This Offer?

As Seen in CFO Studio Magazine Q4 2015 Issue

By John Moskonas President, The ARGroup of Search Companies

How to decide if you should change your current situation

One of the best times to reflect on what is really important to you in terms of your career and life is when you are deciding whether or not to accept an offer. Even if you are simply entertaining the thought of moving on, consider that this is a time to do big-picture thinking. You might consider: compensation, location, balance in life, peer relationship development, and whether or not you can leverage a larger role later on, inside or outside the company.

These factors are not all equal. Aging parents, children in school, and other life circumstances can mean that you need to balance your work life with personal commitments. Compensation is always a good driver, but sometimes not the overriding factor. Whatever your considerations are, however, you should go beyond drawing the proverbial line down the middle of the paper and listing the pros and cons of a role. Weight each factor, because frankly, some things are worth more than others.

Step 1

List what is important to you on the left. Assign a weight on a 10-point scale, where 10 is very important to you and 1 is of little importance. Add up the weights for a total possible score.

Step 2

Rank the components of the offer (or current situation) relative to the weights. For example, if you weight “money” as an 8 and the offer you receive meets those needs, rank the offer an 8. If you weight “no travel” as a 7 and the offer you receive requires you to travel more than you want, you can rank the offer for that category a 5, and so on. Add up those scores.

Step 3

Divide the offer score by the total possible score, for a percentage. If the role ranks 80 percent or better, you may consider that a good offer… or you may not. Perhaps you were looking for a 90 percent or 95 percent. It’s up to you.

Sometimes circumstances dictate that we have to change our situation, sometimes our situation meets our needs. Whatever the case, this is a good way to quantify and/or reevaluate every few years in terms of what is important to you, and use that as a base line. Best wishes!